经颈动脉与经胸途径行经导管主动脉瓣置换术的倾向匹配分析
本研究基于STS/ACC TVT注册数据,比较经颈动脉与经胸(经心尖/经主动脉)途径行SAPIEN 3经导管主动脉瓣置换术的30天结局。倾向匹配分析显示经颈动脉途径与更低的死亡率、新发房颤、再入院率及更短的住院和ICU时间相关,卒中和大血管并发症无显著差异。
要点
- 经颈动脉TAVR较经胸途径30天死亡率更低(4.2% vs 7.7%)。
- 经颈动脉途径新发房颤、再入院更少,住院和ICU时间更短。
- 两组卒中和大血管并发症发生率相似。
核心结论
- 经颈动脉途径TAVR与更低的30天死亡率、更少新发房颤、更短ICU和总住院时间、更少再入院及更大KCCQ评分改善相关,卒中和大血管并发症无显著差异。
研究设计与样本
- 基于STS/ACC TVT注册的倾向匹配分析,纳入2015年6月至2019年7月使用SAPIEN 3瓣膜行经颈动脉、经心尖或经主动脉TAVR的患者,匹配后经颈动脉667例与经胸1334例比较。
主要发现
- 经颈动脉组30天死亡率为4.2%,经胸组为7.7%(P = .004)。
- 经颈动脉组新发房颤为2.2%,经胸组为12.1%(P < .0001)。
- 经颈动脉组30天再入院率为9.8%,经胸组为16.1%(P = .0006)。
- 经颈动脉组中位住院时间为3.0天,经胸组为6.0天(P < .0001);中位ICU时间为25小时 vs 47.2小时(P < .0001)。
- 经颈动脉组30天KCCQ评分较基线改善25.1,经胸组为20.8(P = .007);卒中(4.3% vs 3.7%,P = .44)和大血管并发症(1.4% vs 1.9%,P = .40)相似。
临床怎么用
- 对于不适合经股动脉入路的TAVR患者,经颈动脉途径可作为经胸途径的替代选择,可能改善30天结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transcarotid access for transcatheter aortic valve replacement is emerging as an alternative to more traditional nonfemoral access options such as transapical or transaortic; however, comparative data are limited. The purpose of the study was to analyze outcomes after transcatheter aortic valve replacement using transcatheter compared with transthoracic (transapical/transaortic) access. METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry was queried for patients who underwent transcarotid, transapical, or transaortic transcatheter aortic valve replacement with the SAPIEN 3 (Edwards Lifesciences, Irvine, Calif) transcatheter heart valve between June 2015 and July 2019. Thirty-day unadjusted outcomes were evaluated, and propensity score matching and logistic regression were used to compare transcatheter access with transthoracic access. RESULTS: In the propensity-matched analysis, 667 transcarotid transcatheter aortic valve replacement procedures were compared with 1334 transthoracic procedures. Transcarotid transcatheter aortic valve replacement was associated with lower mortality (4.2% vs 7.7%, P = .004), less new-onset atrial fibrillation (2.2% vs 12.1%, P < .0001), fewer readmissions at 30 days (9.8% vs 16.1%, P = .0006), shorter median length of stay (3.0 vs 6.0 days, P < .0001), shorter median intensive care unit stay (25 vs 47.2 hours, P < .0001), and greater 30-day Kansas City Cardiomyopathy Questionnaire score improvement from baseline (25.1 vs 20.8, P = .007). Stroke (4.3% vs 3.7%, P = .44) and major vascular complications (1.4% vs 1.9%, P = .40) were similar. CONCLUSIONS: Transcatheter aortic valve replacement using transcarotid access is associated with lower 30-day mortality, less atrial fibrillation, shorter intensive care unit and overall length of stay, fewer readmissions, greater improvement in Kansas City Cardiomyopathy Questionnaire scores, and no significant difference in stroke or major vascular complications compared with transthoracic access.
引用
- Allen KB, Chhatriwalla AK, Saxon J, et al. Transcarotid versus transthoracic access for transcatheter aortic valve replacement: A propensity-matched analysis. J Thorac Cardiovasc Surg. 2020. PMID: 33229170. doi:10.1016/j.jtcvs.2020.09.133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。